Title: Editorial: a strategy to optimise the business value of Intellectual Property
Authors: Michael J. Lynskey
Addresses: St. John's College, University of Cambridge, Cambridge, CB2 1TP, UK
Abstract: In this paper, we suggest that, although Intellectual Property (IP) is an intangible asset of a firm, it is now treated effectively as if it were a tangible product. It is also a strong determinant of the success of biotechnology firms, since it is assessed carefully by investors, potential partners and acquirers, who understand that the value of a biotechnology firm is ultimately related to the sophistication with which it operates in the IP arena. As such, we propose that a viable corporate strategy should be one that recognises IP as an activity, like research and development, as part of a value chain, and which can only create value in combination with other production factors. A well-defined, cohesive strategy should deliver a balanced and effective IP production process, to ensure that what is protected and leveraged by firms is of real business value and has the best chance of being licensed.
Keywords: intellectual property; IP; licensing; patents; value chain; biotechnology; bioentrepreneurship; entrepreneurship; corporate strategy.
International Journal of Biotechnology, 2006 Vol.8 No.3/4, pp.146 - 168
Published online: 15 Mar 2006 *
Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article